Hematology Oncology and Stem Cell Therapy Hematology Oncology and Stem Cell Therapy RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Predictors of outcome in patients with hematologic malignancies admitted to the intensive care unit
ConclusionOverall hospital outcome of critically ill patients with HM is improving. However those who require mechanical ventilation or underwent allogeneic HSCT continue to have poor outcome. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Myeloid sarcoma with megakaryoblastic differentiation presenting as a breast mass
We report a case of myeloid sarcoma with megakaryoblastic differentiation in the breast of a patient with history of essential thrombocythemia. The mass was composed of undifferentiated pleomorphic malignant cells in trabecular cords and nests with many scattered giant malignant cells and brisk abnormal mitoses. On immunohistochemistry, the neoplastic cells were positive for CD61, CD31, CD34, Factor VIII and CD43 which confirmed the diagnosis. To our knowledge, this is the first report of myeloid sarcoma with megakaryoblastic morphology occurring in the breast. Here we discuss the clinicopathologic features of this rare en...
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Sorafenib-induced tumor lysis syndrome in a patient with metastatic hepatocellular carcinoma
We describe the case of a young patient with metastatic hepatocellular cancer who developed rapid and fatal tumor lysis syndrome following initiation of sorafenib therapy. Although rare with sorafenib therapy for hepatocellular carcinoma, tumor lysis syndrome is serious complication. Patients with a high burden of disease at therapy initiation should have their metabolic parameters measured prior to starting therapy and closely followed for the first 1–2 weeks while being treated. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Vinorelbine-Cyclophosphamide compared to cyclophosphamide in peripheral blood stem cell mobilization for multiple myeloma
ConclusionVino-Cy is a potential alternative to Cy given the need for effective mobilisation protocols with acceptable toxicity. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Intravenous compared to oral busulfan with cyclophosphamide for autologous hematopoietic cell transplant conditioning for plasma cell myeloma
Publication date: Available online 24 April 2018Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Moaath Mustafa Ali, Donna M. Corrigan, Lisa A. Rybicki, Melissa A. Yurch, Kelly Cherni, Hien Liu, Robert Dean, Betty Hamilton, Brad Pohlman, Steven Andresen, Matt Kalaycio, Brian J. Bolwell, Navneet S. Majhail, Ronald Sobecks (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Diagnostic utility of glycosyltransferase mRNA expression in gastric cancer
ConclusionThis study revealed the potential of ppGalNAc-T6 and ST6GalNAc-I mRNA transcript levels in serum as markers of gastric cancer. Further studies on the wider range of glycosyltransferases in various cancers are needed to establish signature mRNA batteries as minimally invasive markers of gastric cancer. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Current frontline endocrine treatment options for women with hormone receptor-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced-stage breast cancer
Publication date: Available online 19 May 2018Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Hikmat Abdel-RazeqAbstractDespite the recent advances in breast cancer early detection and awareness, a significant portion of patients present with an advanced-stage disease and more patients will progress to stage IV despite adequate treatment of their initial early-stage disease. Hormone receptor (HR)-positive, Human Epidermal Growth Factor Receptor-2 (HER2)-negative subtype is the commonest among all breast cancer subtypes. The management of the advanced-stage disease of this subtype has evolved significantly over ...
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Bizarre multilobated myeloma cells mimicking megakaryocytes
Publication date: Available online 19 May 2018Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Sunil Pasricha, Neha Singh, Ajit Panaych, Anurag Mehta (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Limited role of bone marrow biopsy for detection of marrow involvement in patients with Hodgkin lymphoma from the Middle East and North Africa region
Publication date: June 2018Source: Hematology/Oncology and Stem Cell Therapy, Volume 11, Issue 2Author(s): Moussab Damlaj, Gamal Gmati, Ghulam Syed, Tabrez Pasha, Hend Salama, Osama Ali, Khadega A. Abuelgasim, Mohsen Al-Zahrani, Ahmad Al Askar, Ayman Alhejazi (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations
ConclusionDNMT3A R882 mutation plays an important role in CN-AML patients’ prognosis and clinical outcomes in the presence and absence of NPM1 and FLT3 mutations. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Age adjusted hematopoietic stem cell transplant comorbidity index predicts survival in a T-cell depleted cohort
ConclusionsDespite our small sample population, HCT-CI/Age was more discriminative to identify patients with poor outcome that might benefit from intensified management strategies or other therapeutic approaches rather than allogeneic HCT. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Haploidentical transplantation as a promising therapy for relapsed hemophagocytic lymphohistiocytosis in an older adult patient
Publication date: June 2018Source: Hematology/Oncology and Stem Cell Therapy, Volume 11, Issue 2Author(s): Ernesto Ayala, Denise LaFave, Taiga Nishihori, Mohamed A. Kharfan-DabajaAbstractHemophagocytic lymphohistiocytosis (HLH) is a rare but severe and often overwhelming systemic hyper-inflammatory syndrome generally presenting with unexplained fevers, hepatosplenomegaly, and progressive multi-organ dysfunction. Treatment of HLH has two major goals: Halting the triggering event and controlling the overactive immune system. However, patients with primary or recurrent secondary HLH should subsequently undergo allogeneic HCT ...
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Acute promyelocytic leukemia with increased bone marrow reticulin fibrosis: Description of three cases and review of the literature
Publication date: June 2018Source: Hematology/Oncology and Stem Cell Therapy, Volume 11, Issue 2Author(s): Iman Abou Dalle, Samer Nassif, Ali BazarbachiAbstractPathologic increase in bone marrow reticulin fibrosis can be present in many malignant hematopoietic diseases. In acute leukemia, one-third of patients have some degree of marrow reticulin fibrosis at presentation, which is thought to be related to cytokine release from blasts. Marrow fibrosis is particularly common in acute megakaryoblastic leukemia, while this change is rarely seen in acute promyelocytic leukemia. Six case reports of acute promyelocytic leukemia w...
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Presence of fluorescent in situ hybridization abnormalities is associated with plasma cell burden in light chain amyloidosis
ConclusionWe conclude that in AL, FISH abnormalities are associated with clonal burden. We found no impact of these markers on the type of organ involvement or 1-year survival. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research

Anemia in patient with primary hyperoxaluria and bone marrow involvement by oxalate crystals
We present a rare case of anaemia secondary to bone marrow infiltration by oxalate crystals and renal failure in a patient diagnosed with primary hyperoxaluria. In our case, the anaemia was recovered after the double liver and kidney transplantation, the latter was performed on two occasions after the failure of the first graft. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2018 Category: Cancer & Oncology Source Type: research